Synonyms: SPM-8272 | SPM-907 | Toviaz®
fesoterodine is an approved drug (EMA (2007), FDA (2008))
Compound class:
Synthetic organic
Comment: The marketed formulation contains the fumarate compound (PubChem CID 9849808). Fesoterodine is an antimuscarinic prodrug, with the active metabolite being 5-hydroxymethyl tolterodine (5-HMT, PubChem CID 9819382).
View more information in the IUPHAR Pharmacology Education Project: fesoterodine |
|
No information available. |
Summary of Clinical Use |
Approved to treat the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that occur in patients with overactive bladder syndrome. |
Mechanism Of Action and Pharmacodynamic Effects |
Fesoterodine is an antagonist of muscarinic acetylcholine receptors M2 and M3. Antimuscarinic drugs are the main treatment option for overactive bladder syndrome [1]. Drug action relaxes the smooth muscle of the bladder wall, increasing volume and decreasing urgency. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |